US 7,456,149 B2
	ALK7 and myostatin inhibitors and uses thereof
John Knopf, Carlisle, Mass. (US); and Jasbir Seehra, Lexington, Mass. (US)
Assigned to Acceleron Pharma, Inc., Cambridge, Mass. (US)
Filed on Mar. 02, 2005, as Appl. No. 11/71,686.
Claims priority of provisional application 60/549352, filed on Mar. 02, 2004.
Prior Publication US 2006/0030522 A1, Feb. 09, 2006
Int. Cl. A61K 38/16 (2006.01); C12N 15/11 (2006.01); C12N 15/13 (2006.01)

U.S. Cl. 514—2  [514/12; 424/133.1; 424/178.1; 435/69.7]

4 Claims

1. A pharmaceutical preparation for inhibiting myostatin, comprising a myostatin inhibitor that binds to myostatin in a manner that inhibits binding of an ALK7 receptor to myostatin, which preparation is substantially free of pyrogenic materials so as to be suitable for administration to a mammal, wherein the myostatin inhibitor is a fusion protein comprising i) a ligand binding domain of an ALK7 receptor which binds selectively to myostatin relative to BMP3 and competes with the binding of an ALK7 receptor and ii) an immunoglobulin Fc domain.